The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.

The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.

BCL6 is a transcriptional repressor that is over-expressed due to chromosomal translocations, or other abnormalities, in ∼40% of diffuse large B-cell lymphoma. BCL6 interacts with co-repressor, SMRT, and this is essential for its role in lymphomas. Peptide or small molecule inhibitors, which prevent...

Full description

Bibliographic Details
Main Authors: Sian E Evans, Benjamin T Goult, Louise Fairall, Andrew G Jamieson, Paul Ko Ferrigno, Robert Ford, John W R Schwabe, Simon D Wagner
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3942486?pdf=render

Internet

http://europepmc.org/articles/PMC3942486?pdf=render

Similar Items